NEW YORK (GenomeWeb News) – ChanTest has won a $4.8 million grant from the State of Ohio that it plans to use to expand its G-protein coupled receptor and ion channel products and services, the company said today.

The Cleveland-based company received the competitive grant through Ohio's Third Frontier Research and Commercialization Program

The company plans to use the funds to expand its library of validated ion channel and GPCR cell line products and services, and on its electrogenic transporter and stem-cell derived heart cell services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.